Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/9408
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNaitoh, Mareoen
dc.contributor.authorRisvanis, Johnen
dc.contributor.authorBalding, Leanne Cen
dc.contributor.authorJohnston, Colin Ien
dc.contributor.authorBurrell, Louise Men
dc.date.accessioned2015-05-15T22:29:33Z
dc.date.available2015-05-15T22:29:33Z
dc.date.issued2002-04-01en
dc.identifier.citationCardiovascular Research; 54(1): 51-7en
dc.identifier.govdoc12062361en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/9408en
dc.description.abstractTo assess the long-term efficacy of vasopressin (AVP) V(1a) and V(2) receptor blockade with conivaptan, alone and in combination with angiotensin converting enzyme (ACE) inhibition on blood pressure, metabolic and neurohormonal parameters, and cardiovascular structure in a rat model of congestive heart failure (CHF).CHF was induced by left coronary artery ligation. CHF rats received conivaptan (1 mg/kg/day), ACE inhibition (captopril, 50 mg/kg/day), conivaptan and captopril (Combination) or vehicle for 4 weeks. Blood pressure was measured weekly, metabolic caging studies performed at 25 days, and rats killed and blood and tissue collected after 4 weeks treatment.Combination treatment lowered blood pressure (P<0.01), and conivaptan and Combination caused an aquaresis (P<0.01). Combination decreased plasma natriuretic peptide (P<0.05), reduced left and right ventricular mass (P<0.01) and lung mass (P<0.05).In CHF, blockade of vasopressin V(1a) and V(2) receptors was associated with increased water excretion, and the combination of conivaptan with ACE inhibition was the only treatment to reduce blood pressure, natriuretic peptide and pulmonary congestion. These results suggest conivaptan may be a useful addition to ACE inhibitors in the management of vasoconstriction and fluid retention that characterizes CHF.en
dc.language.isoenen
dc.subject.otherAnalysis of Varianceen
dc.subject.otherAngiotensin-Converting Enzyme Inhibitors.therapeutic useen
dc.subject.otherAnimalsen
dc.subject.otherAntidiuretic Hormone Receptor Antagonistsen
dc.subject.otherArginine Vasopressin.blooden
dc.subject.otherAtrial Natriuretic Factor.blooden
dc.subject.otherBenzazepines.therapeutic useen
dc.subject.otherBlood Pressure.drug effectsen
dc.subject.otherCaptopril.therapeutic useen
dc.subject.otherFemaleen
dc.subject.otherHeart Failure.drug therapy.pathologyen
dc.subject.otherMyocardium.pathologyen
dc.subject.otherOsmolar Concentrationen
dc.subject.otherRatsen
dc.subject.otherRats, Sprague-Dawleyen
dc.subject.otherRenin.blooden
dc.titleNeurohormonal antagonism in heart failure; beneficial effects of vasopressin V(1a) and V(2) receptor blockade and ACE inhibition.en
dc.typeJournal Articleen
dc.identifier.journaltitleCardiovascular researchen
dc.identifier.affiliationDepartment of Medicine, University of Melbourne, Austin and Repatriation Medical Centre, Heidelberg, Victoria 3084, Australiaen
dc.description.pages51-7en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/12062361en
dc.type.austinJournal Articleen
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextWith Fulltext-
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextopen-
crisitem.author.deptCardiology-
crisitem.author.deptGeneral Medicine-
crisitem.author.deptMedicine (University of Melbourne)-
Appears in Collections:Journal articles
Files in This Item:
File Description SizeFormat 
12062361.pdf268.26 kBAdobe PDFThumbnail
View/Open
Show simple item record

Page view(s)

16
checked on Feb 2, 2023

Download(s)

48
checked on Feb 2, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.